Auxolytic, a biotech company founded by Stanford University academics, has described how knocking down a gene called UMPS could render T-cell therapies ineffective by depriving T cells of the nutrition uridine. Xon could also be tailored to work with cancer CAR-T cell therapy, according to the ...
A repeated dose of 400 mg could be given to patients for whom the first dose is ineffective. They have further suggested that no more than two doses be given and the maximum dose single dose must not exceed 800 mg [109]. To date, there are 22 registered trials in progress focused on...